GSC
ACRV icon

Ground Swell Capital’s Acrivon Therapeutics ACRV Stock Holding History

Ground Swell Capital’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,215
Closed -$14.5K – 133
2025
Q2 		$14.5K Buy
+12,215
New +$16.8K 0.02% 114

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ground Swell Capital's ACRV Position: Q3 2025 in Review

Ground Swell Capital sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 12,215 shares — an estimated $14.5K sold.

Ground Swell Capital first reported a position in ACRV in Q2 2025 and held it in 1 quarter. The position peaked at $14.5K in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

  • Ground Swell Capital reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 12,215 Acrivon Therapeutics shares in Q3 2025, an estimated $14.5K.
  • Ground Swell Capital first reported a position in Acrivon Therapeutics in Q2 2025 and held it in 1 quarter.
  • Ground Swell Capital's Acrivon Therapeutics position peaked at $14.5K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.